Skip to main
NUVL

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 21%
Buy 37%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients. With FDA acceptance of its NDA for neladalkib in ALK+ NSCLC patients and promising data on its lead candidate zidesamtinib, we are optimistic about the company's future. We maintain an OUTPERFORM rating and a PT of $125 based on a sum-of-parts valuation with discounted sales multiples for NVL-520 and NVL-655, and acknowledge potential risks from clinical results and competition.

Bears say

Nuvalent is demonstrating strong potential with their small molecule treatments for cancer, but the company's negative financials, including a high risk-adjusted discount rate and low sales projections, suggest that they may struggle to meet their goals and achieve profitability in the near future. The recent analysis of their ARROS-1 study also raises concerns about the effectiveness of their treatment in heavily pretreated patients. These factors contribute to a negative outlook on Nuvalent's stock.

Nuvalent (NUVL) has been analyzed by 19 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 37% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 19 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Jun 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $133.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $133.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.